More articles from Sarcoma/ Melanoma

You have access
Prediction of Treatment Outcome and Survival Using ¹⁸F-FDG PET/CT Radiomic Features and Standard Biomarkers in Patients with Advanced Melanoma Treated Using Dual Immune Checkpoint Inhibitor Therapy
John Crandall, Noah Wasserman and Richard Wahl

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1704;
You have access
¹⁸F-FDG PET/CT in primary prostate synovialsarcoma
Fangfang Chao and Xingmin Han

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1118;
You have access
Nuclear Medicine Lymphoscintigraphy
Noha Aboueldahab

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1117;
You have access
Change of clinical management through serial FDG-PET/CT in patients with FDG-positive adverse events under immunotherapy
Mona Mustafa, Yize Zhuwu, Angela Krackhardt, Stephan Nekolla, Markus Schwaiger and Wolfgang Weber

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 648;
You have access
A comparative study of 18F-FDG PET/CT maximum standardized uptake value with histopathological grading and Ki-67 in soft tissue sarcomas before treatment
Xiaobo Niu and Xingmin Han

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 640;
You have access
Prognostic Value of metabolic parameters on Pretreatment F-18 FDG PET/CT in Patients with Advanced melanoma treated with Pembrolizumab
Kimiteru Ito, Laure Michaud, Reiko Nakajima, Wolfgang Weber and Heiko Schoder

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 646;
You have access
Dynamic ¹⁸F-BPA PET: Differences between radioresistant soft tissue sarcoma and glioblastoma multiforme
Takahiro Morita, Hiroaki Kurihara, Jun Hatazawa and Masahiko Kusumoto

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 641;
You have access
Image-based biomarkers for bone sarcomas using F-18 FDG PET/CT: determination of optimal parameters and their prognostic threshold
Katharina Kneer, Elham Yousefzadeh-Nowshahr, Deborah Weiss, Regine Mayer-Steinacker, Meinrad Beer, Vikas Prasad, Gerhard Glatting and Ambros Beer

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 643;
You have access
F-18 FDG PET/CT for monitoring immunotherapy with PD-1 blockade in patients with advanced melanoma
Kimiteru Ito, Reiko Nakajima, Laure Michaud, Wolfgang Weber and Heiko Schoder

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 645;
You have access
Response assessment and immune-related adverse events as detected by FDG PET/CT in patients treated with combined CTLA-4 and PD-1 checkpoint inhibitors as first-line therapy in advanced melanoma
Amir Iravani, Medhat Osman, Michael Hofman, Alison Weppler, George Au- Yeung, Shahneen Sandhu and Rodney Hicks

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 647;

Main menu

User menu

Search

More articles from Sarcoma/ Melanoma

Pages